# Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

> **NCT04905667** · PHASE1 · COMPLETED · sponsor: **Genor Biopharma Co., Ltd.** · enrollment: 87 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** GB221
- **DRUG:** Herceptin

## Key facts

- **NCT ID:** NCT04905667
- **Lead sponsor:** Genor Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-13
- **Primary completion:** 2020-09-08
- **Final completion:** 2020-09-11
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2021-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04905667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04905667, "Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04905667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*